Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Gains from Sales and Divestitures (2016 - 2017)

BeOne Medicines (BEIGF) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $268750.0 as the latest value for Q4 2017.

  • Quarterly Gains from Sales and Divestitures rose 504.68% to $268750.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $268750.0 through Dec 2017, up 504.68% year-over-year, with the annual reading at $268750.0 for FY2017, 504.68% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2017 was $268750.0 at BeOne Medicines, up from $44445.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $533333.0 in Q4 2015, with the low at $44445.0 in Q4 2016.
  • Average Gains from Sales and Divestitures over 3 years is $282176.0, with a median of $268750.0 recorded in 2017.
  • The sharpest move saw Gains from Sales and Divestitures plummeted 91.67% in 2016, then skyrocketed 504.68% in 2017.
  • Over 3 years, Gains from Sales and Divestitures stood at $533333.0 in 2015, then tumbled by 91.67% to $44445.0 in 2016, then surged by 504.68% to $268750.0 in 2017.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $268750.0, $44445.0, and $533333.0 for Q4 2017, Q4 2016, and Q4 2015 respectively.